Faculty Opinions recommendation of Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.

2010 ◽  
Author(s):  
Katie Janeway ◽  
Allison O'Neill
Keyword(s):  
Gene Expression ◽  
Clinical Outcome ◽  
Gene Expression Signature ◽  
Expression Signature ◽  
Genome Complexity

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

2010 ◽  
Vol 16 (7) ◽  
pp. 781-787 ◽  
Author(s):  
Frédéric Chibon ◽  
Pauline Lagarde ◽  
Sébastien Salas ◽  
Gaëlle Pérot ◽  
Véronique Brouste ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Outcome ◽  
Gene Expression Signature ◽  
Expression Signature ◽  
Genome Complexity

scholarly journals Pan-cancer association of a centrosome amplification gene expression signature with genomic alterations and clinical outcome

2019 ◽  
Vol 15 (3) ◽  
pp. e1006832 ◽  
Author(s):  
Bernardo P. de Almeida ◽  
André F. Vieira ◽  
Joana Paredes ◽  
Mónica Bettencourt-Dias ◽  
Nuno L. Barbosa-Morais
Keyword(s):  
Gene Expression ◽  
Clinical Outcome ◽  
Gene Expression Signature ◽  
Centrosome Amplification ◽  
Genomic Alterations ◽  
Expression Signature ◽  
Pan Cancer

scholarly journals Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer

2016 ◽  
Vol 23 (1) ◽  
pp. 77-93 ◽  
Author(s):  
Aurélien J.C. Pommier ◽  
Matthew Farren ◽  
Bhavika Patel ◽  
Mark Wappett ◽  
Filippos Michopoulos ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Clinical Outcome ◽  
Gene Expression Signature ◽  
Expression Signature ◽  
Metabolic Gene ◽  
Metabolic Gene Expression ◽  
Vegf Inhibition

scholarly journals A Radiation-Derived Gene Expression Signature Predicts Clinical Outcome for Breast Cancer Patients

2009 ◽  
Vol 171 (2) ◽  
pp. 141-154 ◽  
Author(s):  
Brian D. Piening ◽  
Pei Wang ◽  
Aravind Subramanian ◽  
Amanda G. Paulovich
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Gene Expression Signature ◽  
Breast Cancer Patients ◽  
Expression Signature

Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 533-533
Author(s):  
S. Loi ◽  
B. Haibe-Kains ◽  
F. Lallemand ◽  
L. Pusztai ◽  
A. Bardelli ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Outcome ◽  
Expression Profiles ◽  
Pik3ca Mutation ◽  
Gene Expression Signature ◽  
Pi3k Pathway ◽  
Mutation Status ◽  
Luminal B ◽  
Pik3ca Mutations ◽  
Expression Signature

533 Background: The phosphathidylinositol-3-kinase (PI3K) signaling pathway is frequently deregulated in tumor biology and is an attractive target for cancer therapy. Our aim was to characterize the molecular and clinical outcome effects of PIK3CA mutations in breast cancer (BC). Methods: We analyzed 173 BC samples for PIK3CA mutations. Corresponding gene expression profiles were used to understand its effects on the PI3K pathway. We validated a PIK3CA-GS in 2 independent BC cohorts (n = 183) with known PIK3CA mutation status and evaluated its correlation with clinical outcome in 1748 BC samples stratified by treatment and subtype. Results: 26% of BCs had a PIK3CA mutation. Tumors with PIK3CA mutation demonstrated a distinct gene expression signature (p = 0.03 after 1000 perm). In 2 datasets it could discriminate PIK3CA mutation carriers from wild-type (ROC 0.68, 0.71, p = 0.001for both). However, the PIK3CA-GS was correlated with deactivation of the PI3K pathway probably through a negative feedback loop. This observation was supported by: 1) the PIK3CA-GS was significantly correlated with gene expression changes induced by PI3K inhibitors (Connectivity Map, Gene set enrichment analyses) and 2) the PIK3CA-GS was anti-correlated with a GS of PTEN loss (R = -0.3; Saal et al, 2007). Higher levels of the PIK3CA signature were observed in HER-2+ and estrogen receptor positive (ER+), luminal BC subtypes. Whilst there was no association with mutation status alone and prognosis, increasing expression of the PIK3CA-GS (suggesting deactivation) was significantly associated with better clinical outcome in both untreated (p = 0.04) and particularly ER+, luminal-B, tamoxifen only-treated (p = 0.004) BC. Multivariate analysis (HR: 0.4; 95%CI: 0.3–0.7; p = 0.002) confirmed that the PI3KCA-GS provided independent prognostic information. Conclusions: Paradoxically, the PIK3CA-GS correlates with inhibition of the PI3K pathway in ER+ BC and identifies a subgroup of luminal B BCs with a favorable outcome. The PIK3CA-GS may be a better indicator of PI3K pathway dysfunction than mutation status, potentially indicating patients who may benefit from combined endocrine therapy and PI3K inhibition. No significant financial relationships to disclose.

scholarly journals HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome

Oncogene ◽  
2013 ◽  
Vol 33 (8) ◽  
pp. 1017-1026 ◽  
Author(s):  
J Wardwell-Ozgo ◽  
T Dogruluk ◽  
A Gifford ◽  
Y Zhang ◽  
T P Heffernan ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Outcome ◽  
Tumor Growth ◽  
Gene Expression Signature ◽  
Melanoma Tumor ◽  
Expression Signature ◽  
Tumor Growth And Metastasis
Sign in / Sign up

Export Citation Format

Share Document